Voluntary Recall of Takeda's Alinamin in Japan

Takeda Pharmaceutical Company Limited (“Takeda”) today received an Order for Corrective Action regarding the manufacturing and marketing of ALINAMIN-F5 Injection from the Osaka Prefectural Government, citing a violation of the Pharmaceutical Affairs Act associated with the voluntary recall of ALINAMIN-F5 Injection, Lot H123. Also today, the manufacturing site of this product, the Osaka Plant (located in Izumisano City) of NIHON PHARMACEUTICAL CO., LTD, a contract manufacturer and subsidiary of Takeda, received the order for temporary suspension of its operations from the Osaka Prefectural Government for the period of 12 days from February 14 to February 25.